Immune Evasion by the Highly Mutated SARS-CoV-2 Omicron Variant

References

• Guruprasad L. Human SARS CoV-2 spike protein mutations. Proteins. 2021;89(5):569–576. doi:10.1002/prot.26042
   PubMed Web of Science ®Google Scholar
• WHO. Tracking SARS-CoV-2 variants; 2021. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. Accessed July 19, 2022.
   Google Scholar
• O’Toole Á, Scher E, Underwood A, et al. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evol. 2021;7(2):veab064. doi:10.1093/ve/veab064
   PubMed Web of Science ®Google Scholar
• Classification of Omicron (B. 1.1. 529): SARS-CoV-2 variant of concern; 2021. Available from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern. Accessed July 19, 2022.
   Google Scholar
• Gao SJ, Guo H, Luo G. Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert! J Med Virol. 2022;94:1255–1256. doi:10.1002/jmv.27491
   PubMed Web of Science ®Google Scholar
• COVID C, Team R. SARS-CoV-2 B. 1.1. 529 (Omicron) variant—United States, December 1–8, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(50):1731–1734. doi:10.15585/mmwr.mm7050e1
   Web of Science ®Google Scholar
• Jung C, Kmiec D, Koepke L, et al. Omicron: what makes the latest SARS-CoV-2 variant of concern so concerning? J Virol. 2022;96(6):e02077–21. doi:10.1128/jvi.02077-21
   Web of Science ®Google Scholar
• Bansal K, Kumar S. Mutational cascade of SARS-CoV-2 leading to evolution and emergence of omicron variant. Virus Res. 2022;315:198765. doi:10.1016/j.virusres.2022.198765
   PubMed Web of Science ®Google Scholar
• Majumdar S, Sarkar R. Mutational and phylogenetic analyses of the two lineages of the Omicron variant. J Med Virol. 2022;94(5):1777–1779. doi:10.1002/jmv.27558
   Web of Science ®Google Scholar
• Schubert M, Bertoglio F, Steinke S, et al. Human serum from SARS-CoV-2 vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant. BMC Med. 2022;20:102. doi:10.1186/s12916-022-02312-5
   Web of Science ®Google Scholar
• Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and delta variant of SARS‐CoV‐2: a comparative computational study of spike protein. J Med Virol. 2022;94:1641–1649. doi:10.1002/jmv.27526
   PubMed Web of Science ®Google Scholar
• Wilhelm A, Widera M, Grikscheit K, et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. medRxiv Preprint. 2021. doi:10.1101/2021120721267432
   Google Scholar
• Kumar S, Karuppanan K, Subramaniam G. Omicron (BA.1) and sub-variants (BA.1, BA.2 and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: a comparative sequence and structural-based computational assessment. bioRxiv. 2022. doi:10.1002/jmv.27927
   Google Scholar
• Dejnirattisai W, Huo J, Zhou D, et al. Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467–84.e15. doi:10.1016/j.cell.2021.12.046
   PubMed Web of Science ®Google Scholar
• Lubin JH, Markosian C, Balamurugan D, et al. Structural models of SARS-CoV-2 Omicron variant in complex with ACE2 receptor or antibodies suggest altered binding interfaces. bioRxiv. 2021. doi:10.1101/2021.12.12.472313
   Google Scholar
• Shah M, Woo HG. Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies. Front Immunol. 2022;12. doi:10.3389/fimmu.2021.830527
   Web of Science ®Google Scholar
• Hu J, Peng P, Wang K, et al. Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. Cell Mol Immunol. 2021;18(4):1061–1063. doi:10.1038/s41423-021-00648-1
   PubMed Web of Science ®Google Scholar
• Cao Y, Su B, Guo X, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell. 2020;182(1):73–84. e16. doi:10.1016/j.cell.2020.05.025
   PubMed Web of Science ®Google Scholar
• Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584(7819):115–119. doi:10.1038/s41586-020-2380-z
   PubMed Web of Science ®Google Scholar
• Lv Z, Deng Y-Q, Ye Q, et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science. 2020;369(6510):1505–1509. doi:10.1126/science.abc5881
   PubMed Web of Science ®Google Scholar
• Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584(7819):120–124. doi:10.1038/s41586-020-2381-y
   PubMed Web of Science ®Google Scholar
• Motozono C, Toyoda M, Zahradnik J, et al. An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity. bioRxiv. 2021. doi:10.1101/20210402438288
   Google Scholar
• Motozono C, Toyoda M, Zahradnik J, et al. An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity. Cell Host Microbe. 2021;29(7):1124–36.e11. doi:10.1016/j.chom.2021.06.006
   PubMed Web of Science ®Google Scholar
• Mengist HM, Kombe Kombe AJ, Mekonnen D, Abebaw A, Getachew M, Jin T. Mutations of SARS-CoV-2 spike protein: implications on immune evasion and vaccine-induced immunity. Semin Immunol. 2021;55:101533. doi:10.1016/j.smim.2021.101533
   PubMed Web of Science ®Google Scholar
• Lu L, Mok BW-Y, Chen L, et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. Clin Infect Dis. 2021. doi:10.1093/cid/ciab1041
   Web of Science ®Google Scholar
• Chen J, Wang R, Gilby NB, Wei G-W. Omicron (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 2022;62(2):412–422. doi:10.1021/acs.jcim.1c01451
   PubMed Web of Science ®Google Scholar
• Rössler A, Riepler L, Bante D, Laer D, Kimpel J. SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals. medRxiv Preprint. 2021. doi:10.1101/2021120821267491
   Google Scholar
• Ranjan P, Neha DC, Devar KA, Das P. The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on vaccine efficacy, its correlation to Delta variants: a computational approach. bioRxiv Preprint. 2021. doi:10.1101/20211206471215
   Google Scholar
• Mannar D, Saville JW, Zhu X, et al. SARS-CoV-2 Omicron variant: antibody evasion and cryo-EM structure of spike protein–ACE2 complex. Science. 2022;375(6582):760–764. doi:10.1126/science.abn7760
   PubMed Web of Science ®Google Scholar
• Tian D, Sun Y, Xu H, Ye Q. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. J Med Virol. 2022;94(6):2376–2383. doi:10.1002/jmv.27643
   PubMed Web of Science ®Google Scholar
• Ahava M, Jarva H, Jääskeläinen A, Lappalainen M, Vapalahti O, Kurkela S. Rapid increase in SARS-CoV-2 seroprevalence during the emergence of Omicron variant, Finland. medRxiv. 2022;41(6):997–999.
   Google Scholar
• Dächert C, Muenchhoff M, Graf A. Rapid and sensitive identification of omicron by variant-specific PCR and nanopore sequencing: paradigm for diagnostics of emerging SARS-CoV-2 variants. Med Microbiol Immunol. 2022;211(1):71–77. doi:10.1007/s00430-022-00728-7
   Web of Science ®Google Scholar
• Regan J, Flynn JP, Choudhary MC, et al. Detection of the Omicron variant virus with the Abbott BinaxNow SARS-CoV-2 rapid antigen assay. Open Forum Infect Dis. 2022;9(3). doi:10.1093/ofid/ofac022
   Google Scholar
• Mostafavi E, Dubey AK, Teodori L, Ramakrishna S, Kaushik A. SARS-CoV-2 Omicron variant: a next phase of the COVID-19 pandemic and a call to arms for system sciences and precision medicine. MedComm. 2022;3(1):e119–e. doi:10.1002/mco2.119
   Google Scholar
• Rabiee N, Rabiee M, Sojdeh S, et al. Porphyrin molecules decorated on metal-organic frameworks for multi-functional biomedical applications. Biomolecules. 2021;11(11):1714. doi:10.3390/biom11111714
   Web of Science ®Google Scholar
• Phan QA, Truong LB, Medina-Cruz D, Dincer C, Mostafavi E. CRISPR/Cas-powered nanobiosensors for diagnostics. Biosens Bioelectron. 2022;197:113732. doi:10.1016/j.bios.2021.113732
   Web of Science ®Google Scholar
• Sharma PK, Kim E-S, Mishra S. Ultrasensitive and reusable graphene oxide-modified double-interdigitated capacitive (DIDC) sensing chip for detecting SARS-CoV-2. ACS Sensors. 2021;6(9):3468–3476. doi:10.1021/acssensors.1c01437
   Web of Science ®Google Scholar
• Tiwari S, Juneja S, Ghosal A, et al. Antibacterial and antiviral high-performance nanosystems to mitigate new SARS-CoV-2 variants of concern. Curr Opin Biomed Eng. 2022;21:100363. doi:10.1016/j.cobme.2021.100363
   PubMedGoogle Scholar
• ECDPC. Implications of the spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA - first update. 2 December 2021. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/en/publications-data/covid-19-threat-assessment-spread-omicron-first-update. Accessed July 19, 2022.
   Google Scholar
• Chen J, Wang R, Gilby NB, Wei G-W. Omicron (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. ArXiv. 2021;62:arXiv:2112.01318v1.
   Google Scholar
• Li M, Lou F, Fan H. SARS-CoV-2 variant Omicron: currently the most complete “escapee” from neutralization by antibodies and vaccines. Signal Transduct Target Ther. 2022;7(1):28. doi:10.1038/s41392-022-00880-9
   PubMed Web of Science ®Google Scholar
• Hu J, Peng P, Cao X, et al. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron. Cell Mol Immunol. 2022;19(2):293–295. doi:10.1038/s41423-021-00836-z
   PubMed Web of Science ®Google Scholar
• Harvey WT, Jackson B, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409–424. doi:10.1038/s41579-021-00573-0
   PubMed Web of Science ®Google Scholar
• Ng KW, Wrobel AG, Gamblin SJ, Kassiotis G, Kassiotis G. Heterologous humoral immunity to human and zoonotic coronaviruses: aiming for the achilles heel. Semin Immunol. 2021;55:101507. doi:10.1016/j.smim.2021.101507
   Web of Science ®Google Scholar
• Bošnjak BSS, Willenzon S, Willenzon S, et al. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cell Mol Immunol. 2021;18(4):936–944. doi:10.1038/s41423-020-00573-9
   Web of Science ®Google Scholar
• Zahradník JMS, Shemesh M, Shemesh M, et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Nat Microbiol. 2021;6(9):1188–1198. doi:10.1038/s41564-021-00954-4
   PubMed Web of Science ®Google Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941–1950. doi:10.1056/NEJMoa2107934
   PubMed Web of Science ®Google Scholar
• VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022;1–6. doi:10.1038/s41591-021-01678-y
   Web of Science ®Google Scholar
• Greaney AJ, Starr TN, Bloom JD. An antibody-escape calculator for mutations to the SARS-CoV-2 receptor-binding domain. bioRxiv Preprint. 2021. doi:10.1101/20211204471236
   Google Scholar
• Woo MS, Woo HG. Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escape approved COVID-19 therapeutic antibodies. Front Immunol. 2022;12:830527.
   Web of Science ®Google Scholar
• Cameroni E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022;602:664–670. doi:10.1038/s41586-021-04386-2
   PubMed Web of Science ®Google Scholar
• Zhou B, Zhou R, Chan JF-W, et al. An elite broadly neutralizing antibody protects SARS-CoV-2 Omicron variant challenge. bioRxiv Preprint. 2022. doi:10.1101/20220105475037
   Google Scholar
• Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602(7898):676–681. doi:10.1038/s41586-021-04388-0
   PubMed Web of Science ®Google Scholar
• Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602(7898):671–675. doi:10.1038/s41586-021-04389-z
   PubMed Web of Science ®Google Scholar
• Laha S, Chakraborty J, Das S, Manna SK, Biswas S, Chatterjee R. Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission. Infect Genet Evol. 2020;85:104445. doi:10.1016/j.meegid.2020.104445
   PubMed Web of Science ®Google Scholar
• Cui Z, Liu P, Wang N, et al. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell. 2022;185(5):860–71.e13. doi:10.1016/j.cell.2022.01.019
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447–56.e11. doi:10.1016/j.cell.2021.12.032
   PubMed Web of Science ®Google Scholar
• Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant. N Engl J Med. 2022;386(10):995–998. doi:10.1056/NEJMc2119407
   PubMed Web of Science ®Google Scholar
• Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization properties of the SARS-CoV-2 Omicron variant. medRxiv Preprint. 2021. doi:10.1101/2021121221267646
   Google Scholar
• Seidel A, Jahrsdörfer B, Körper S, et al. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against SARS-CoV-2 Delta and Omicron that can be predicted by anti-S antibody concentrations in serological assays. medRxiv Preprint. 2022. doi:10.1101/2022011722269201
   Google Scholar
• Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2021;185(3):457–66.e4. doi:10.1016/j.cell.2021.12.033
   Web of Science ®Google Scholar
• Doria-Rose NA, Shen X, Schmidt SD, et al. Booster of mRNA-1273 vaccine reduces SARS-CoV-2 Omicron escape from neutralizing antibodies. medRxiv Preprint. 2021. doi:10.1101/2021.12.15.21267805
   Google Scholar
• Zhang L, Li Q, Liang Z, et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg Microbes Infect. 2022;11(1):1–5. doi:10.1080/22221751.2021.2017757
   PubMed Web of Science ®Google Scholar
• Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2021;11:477–481.
   Web of Science ®Google Scholar
• Faustini S, Shields A, Banham G, et al. Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals. J Infect. 2022;S0163–S4453(22):00002.
   Google Scholar
• Burns M, Bartsch Y, Boribong B, et al. Durability and cross-reactivity of SARS-CoV-2 mRNA vaccine in adolescent children. medRxiv Preprint. 2022. doi:10.1101/2022.01.05.22268617
   Google Scholar
• Cele S, Jackson L, Khoury DS, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv Preprint. 2021. doi:10.1101/2021120821267417
   Google Scholar
• Carreño JM, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. 2022;602:682–688. doi:10.1038/s41586-022-04399-5
   PubMed Web of Science ®Google Scholar
• Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602:657–663. doi:10.1038/s41586-021-04385-3
   PubMed Web of Science ®Google Scholar
• Motozono C, Toyoda M, Zahradnik J, et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe. 2021;29(7):1124–36. e11.
   PubMed Web of Science ®Google Scholar
• Agerer B, Koblischke M, Gudipati V, et al. SARS-CoV-2 mutations in MHC-I–restricted epitopes evade CD8+ T cell responses. Sci Immunol. 2021;6(57):eabg6461. doi:10.1126/sciimmunol.abg6461
   PubMed Web of Science ®Google Scholar
• Redd AD, Nardin A, Kared H, et al. Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals. bioRxiv Preprint. 2021. doi:10.1101/20211206471446
   Google Scholar
• De Marco L, D’Orso S, Pirronello M, et al. Preserved T cell reactivity to the SARS-CoV-2 Omicron variant indicates continued protection in vaccinated individuals. bioRxiv Preprint. 2021. doi:10.1101/2021.12.30.474453:2021.12.30.474453
   Google Scholar
• Redd AD, Nardin A, Kared H, et al. CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants. Open Forum Infect Dis. 2021;8(7):ofab143. doi:10.1093/ofid/ofab143
   Google Scholar
• Liu J, Chandrashekar A, Sellers D, et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature. 2022. doi:10.1038/s41586-022-04465-y
   Web of Science ®Google Scholar
• Mazzoni A, Vanni A, Spinicci M, et al. SARS-CoV-2 spike-specific CD4+ T cell response is conserved against variants of concern, including omicron. Front Immunol. 2022;13:801431. doi:10.3389/fimmu.2022.801431
   PubMed Web of Science ®Google Scholar
• Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063. doi:10.1126/science.abf4063
   PubMed Web of Science ®Google Scholar
• Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861–880. doi:10.1016/j.cell.2021.01.007
   PubMed Web of Science ®Google Scholar
• Goel RR, Painter MM, Apostolidis SA, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374(6572):abm0829. doi:10.1126/science.abm0829
   PubMed Web of Science ®Google Scholar
• McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590(7847):630–634. doi:10.1038/s41586-020-03041-6
   PubMed Web of Science ®Google Scholar
• Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–501. e15. doi:10.1016/j.cell.2020.05.015
   PubMed Web of Science ®Google Scholar
• Naranbhai V, Nathan A, Kaseke C, et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell. 2022;185(6):1041–1051. doi:10.1016/j.cell.2022.01.029
   PubMed Web of Science ®Google Scholar
• GeurtsvanKessel CH, Geers D, Schmitz KS, et al. Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients. Sci Immunol. 2022;7:eabo2202. doi:10.1126/sciimmunol.abo2202
   PubMed Web of Science ®Google Scholar
• Wei C, Shan K-J, Wang W, Zhang S, Huan Q, Qian W. Evidence for a mouse origin of the SARS-CoV-2 Omicron variant. J Genet Genom. 2021;48(12):1111–1121. doi:10.1016/j.jgg.2021.12.003
   PubMed Web of Science ®Google Scholar
• Diseases NIfC. Frequently asked questions for the B.1.1.529 mutated SARS-CoV-2 lineage in South Africa. Johannesburg, South Africa: National Institute for Communicable Diseases; 2021. Available from: https://www.nicd.ac.za/. Accessed December 3, 2021.
   Google Scholar
• Hussey H, Davies M-A, Heekes A, et al. Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections – a survival analysis. Int J Infect Dis. 2022;118:150–154. doi:10.1016/j.ijid.2022.02.051
   Web of Science ®Google Scholar
• Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602(7898):654–656. doi:10.1038/s41586-021-04387-1
   PubMed Web of Science ®Google Scholar
• Chen -L-L, Chua GT, Lu L, et al. Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine. Emerg Microbes Infect. 2022;11(1):543–547. doi:10.1080/22221751.2022.2035195
   PubMed Web of Science ®Google Scholar
• Zhang J, Cai Y, Xiao T, et al. Structural impact on SARS-CoV-2 spike protein by D614G substitution. Science. 2021;372(6541):525–530. doi:10.1126/science.abf2303
   PubMed Web of Science ®Google Scholar
• Yurkovetskiy L, Wang X, Pascal KE, et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell. 2020;183(3):739–51.e8. doi:10.1016/j.cell.2020.09.032
   PubMed Web of Science ®Google Scholar
• Hou YJ, Chiba S, Halfmann P. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020;370(6523):1464–1468. doi:10.1126/science.abe8499
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang T, Fang Y, Liu J, Ye Q, Ding L. SARS-CoV-2 spike L452R mutation increases Omicron variant fusogenicity and infectivity as well as host glycolysis. Signal Transduct Target Ther. 2022;7(1):76. doi:10.1038/s41392-022-00941-z
   Web of Science ®Google Scholar
• Wang B, Goh YS, Prince T, et al. Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. NPJ Vaccines. 2021;6(1):125. doi:10.1038/s41541-021-00389-2
   Web of Science ®Google Scholar
• Zhu X, Mannar D, Srivastava SS, et al. Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies. PLoS Biol. 2021;19(4):e3001237. doi:10.1371/journal.pbio.3001237
   PubMed Web of Science ®Google Scholar
• Mannar D, Saville JW, Zhu X, et al. Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. Cell Rep. 2021;37(12):110156. doi:10.1016/j.celrep.2021.110156
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang Q, Wei P, et al. The basis of a more contagious 501Y. V1 variant of SARS-COV-2. Cell Res. 2021;31(6):720–722. doi:10.1038/s41422-021-00496-8
   Web of Science ®Google Scholar
• Saxena SK, Kumar S, Ansari S, et al. Characterization of the novel SARS‐CoV‐2 Omicron (B. 1.1. 529) variant of concern and its global perspective. J Med Virol. 2022;94(4):1738–1744. doi:10.1002/jmv.27524
   PubMed Web of Science ®Google Scholar
• McCallum M, Czudnochowski N, Rosen LE, et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science. 2022;375(6583):864–868. doi:10.1126/science.abn8652
   PubMed Web of Science ®Google Scholar
• Duan X, Shi R, Liu P, et al. A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants. Signal Transduct Target Ther. 2022;7:23. doi:10.1038/s41392-022-00879-2
   PubMed Web of Science ®Google Scholar
• Khurana A, Allawadhi P, Khurana I, et al. Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Nano Today. 2021;38:101142. doi:10.1016/j.nantod.2021.101142
   PubMed Web of Science ®Google Scholar
• Nel AE, Miller JF. Nano-enabled COVID-19 vaccines: meeting the challenges of durable antibody plus cellular immunity and immune escape. ACS Nano. 2021;15(4):5793–5818. doi:10.1021/acsnano.1c01845
   PubMed Web of Science ®Google Scholar
• Wang F, Li L, Dou Y, et al. Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants. Emerg Microbes Infect. 2022;11(1):548–551. doi:10.1080/22221751.2022.2032374
   PubMed Web of Science ®Google Scholar
• Silva CM, Wanderley CWS, Veras FP, et al. Gasdermin-D activation by SARS-CoV-2 trigger NET and mediate COVID-19 immunopathology. medRxiv Preprint. 2022. doi:10.1101/2022012422269768
   Google Scholar
• Zhou H, Tada T, Dcosta BM, Landau NR. Neutralization of SARS-CoV-2 Omicron BA.2 by therapeutic monoclonal antibodies. bioRxiv Preprint. 2022. doi:10.1101/20220215480166
   Google Scholar
• Tada T, Zhou H, Dcosta BM, et al. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. bioRxiv Preprint. 2021. doi:10.1101/20211228474369
   Google Scholar
• Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369(6506):1010–1014. doi:10.1126/science.abd0827
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238–251. doi:10.1056/NEJMoa2035002
   PubMed Web of Science ®Google Scholar
• Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–644. doi:10.1001/jama.2021.0202
   PubMed Web of Science ®Google Scholar
• Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584(7821):443–449. doi:10.1038/s41586-020-2548-6
   PubMed Web of Science ®Google Scholar
• Lusvarghi S, Pollett SD, Neerukonda SN, et al. SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster. bioRxiv Preprint. 2021. doi:10.1101/20211222473880
   Google Scholar
• Wratil PR, Stern M, Priller A, et al. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nat Med. 2022;28(3):496–503. doi:10.1038/s41591-022-01715-4
   PubMed Web of Science ®Google Scholar
• Muik A, Lui BG, Wallisch A-K, et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera. Science. 2022;375(6581):678–680. doi:10.1126/science.abn7591
   PubMed Web of Science ®Google Scholar
• Pérez-Then E, Lucas C, Monteiro VS, et al. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nat Med. 2022;1. doi:10.1038/s41591-022-01705-6
   Web of Science ®Google Scholar
• Evans JP, Zeng C, Carlin C, et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci Transl Med. 2022;14:1–13.
   Web of Science ®Google Scholar
• Bruel T, Pinaud L, Tondeur L, et al. SARS-CoV-2 Omicron neutralization and risk of infection among elderly after a booster dose of Pfizer vaccine. medRxiv. 2022. doi:10.1101/2022.03.30.22273175
   Google Scholar
• Li P, Wang Y, Lavrijsen M, et al. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022;32(3):322–324. doi:10.1038/s41422-022-00618-w
   PubMed Web of Science ®Google Scholar
• Brakenhoff TB, Franks B, Goodale BM, et al. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial. Trials. 2021;22(1):412. doi:10.1186/s13063-021-05241-5
   Web of Science ®Google Scholar
• Ao D, Lan T, He X, et al. SARS-CoV-2 Omicron variant: immune escape and vaccine development. MedComm. 2022;3(1):e126. doi:10.1002/mco2.126
   Google Scholar
• Hirabara SM, Serdan TDA, Gorjao R, et al. SARS-COV-2 variants: differences and potential of immune evasion. Front Cell Infect Microbiol. 2022;11. doi:10.3389/fcimb.2021.781429
   Web of Science ®Google Scholar
• Okpeku M. Possibility of COVID-19 eradication with evolution of a new omicron variant. Infect Dis Poverty. 2022;11(1):30. doi:10.1186/s40249-022-00951-7
   Web of Science ®Google Scholar
• Robert X, Gouet P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 2014;42(W1):W320–W4. doi:10.1093/nar/gku316
   PubMed Web of Science ®Google Scholar
• Global Initiative on Sharing All Influenza Data (GISAID) database; 2021. Available from: https://www.gisaid.org/. Accessed December 22, 2021.
   Google Scholar